TAGLN2 and neoplasm: As a key tumor suppressor at the 5q31 fragile site, miR-145 plays a central role in urological tumors through epigenetic dysregulation (e.g., methylation) and target gene regulation (Transgelin-2, RAB5C, IGF1, etc.).